

Personal Information



Kasan Seetalarom

Address: Phramongkutklao Hospital

Country: Thailand

Curriculum Vitae

Medical Education

- 1985 Graduate M.D. from Phramongkutklao College of Medicine, Bangkok, Thailand
- 1988-1991 Residency Traing in Internal Medicine at Phramongkutklao College of Medicine, Bangkok, Thailand
- 1995-1997 Fellowship in Medical oncology at M.D. Anderson cancer Center, Houston, Texas, USA

Academic Appointments

- 1992-1995 Instructor in Medicine, Phramongkutklao College of Medicine
- 1995- present Instructor in Medical Oncology, Phramongkutklao College of Medicine

Professional Organizations

Member of The Royal College of Physicians of Thailand

Member of Thailand Society of Clinical Oncology

Published papers

- **Seetalarom K.** Management of cancer Pain. Clinic 1994; 10(4):249-257.
- **Seetalarom K,** Kudelka A, Edwards CL, et al. Prolonged stabilization of advanced fallopian tube cancer with leuprolide acetate. Thai Journal of Obstetrics and Gynecology. 1996; 8(4):347-350.
- **Seetalarom K,** Kudelka A, Verschraegen CF, Kavanagh JJ. Taxanes in ovarian cancer treatment. Current Opinion in Obstretrics and Gynecology 1997; 9:14-20.
- **Seetalarom K.** Nasopharyngeal cancer: Experience form UICC workshop 1998. Royal Thai Army Medical Journal 1999; 51:1-7.

Published chapter in text book

- Seetalarom K. Non-small cell lung cancer. In Vorachai Ratanatharathorn. Cancer Treatment 2 1998
- Sunthornthum S, Seetalarom K, Juthaputhi A. Screening for hepatocellular carcinoma. In Sunthornthumm ed Guideline for screening and health promotion for thai people. 1993;180-6.
- Sunthornthum S, Seetalarom K. Screening for cholangiocarcinoma. In Sunthornthumm ed Guideline for screening and health promotion for thai people. 1993; 187-92.

- Sunthornthum S, Seetalarom K Screening for other GI malignancies. In Sunthornthumm ed Guideline for screening and health promotion for thai people. 1993;202-6.

Clinical Research experiences

1. Herceptin in Adjuvant Breast Cancer, The HERA Trial (Roche) 2002
2. XELOX adjuvant study for colon cancer (Roche) 2003
3. IPASS study in non-small cell lung cancer (Astra zeneca) 2005
4. AVANT study: adjuvant therapy for colon cancer (Roche) 2007
5. FASACT2 study: first-line therapy for non-small cell lung cancer (Roche) 2009
6. ICON study: ipilimumab with first-line chemotherapy for squamous cell lung cancer (BristolMyers Squibb) 2011
7. ASPIRATION study: An open-label study of erlotinib as first line therapy until and beyond RECIST progression in NSCLC patients who harbor EGFR mutation (Roche) 2013